Filings
| Filing | Date | Type | Filed with |
|---|
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
|---|
| RAD interim analysis at SNO26 on RAD101 Phase IIb data | Nov 15, 2026 | Other filings | ASX |
|---|
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
|---|
| Change of Director's Interest Notices x 4 | Nov 10, 2026 | Ownership change notice | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 4, 2026 | Current report | SEC |
|---|
| RAD Alignment with US FDA for Development of RAD101 | Nov 3, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
|---|
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 26, 2026 | Meeting notice | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
|---|
| Radiopharm receives $8M advance on FY26 R&D tax incentive | Oct 26, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 20, 2026 | Current report | SEC |
|---|
| Notification regarding unquoted securities - RAD | Oct 20, 2026 | Other filings | ASX |
|---|
| Change of Director's Interest Notices x 4 | Oct 20, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - RAD | Oct 20, 2026 | Financing | ASX |
|---|
| SCHEDULE 13G · Big-stake notice | Oct 14, 2026 | Big-stake notice | SEC |
|---|
| Non-Compliance with Listing Rule 10.11 | Oct 11, 2026 | Legal or regulatory action | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
|---|
| RAD Completes Meeting with US FDA for Development of RAD101 | Oct 4, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 1, 2026 | Current report | SEC |
|---|
| Notification of cessation of securities - RAD | Oct 1, 2026 | Financing | ASX |
|---|
| Change of Director's Interest Notice (RC) | Oct 1, 2026 | Ownership change notice | ASX |
|---|
| 20-F · Annual report | Sep 30, 2026 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
|---|
| Appendix 4G and Corporate Governance Statement | Sep 30, 2026 | Other filings | ASX |
|---|
| Annual Report and Form 20-F | Sep 30, 2026 | Annual report | ASX |
|---|
| EFFECT · Notice that a registration is effective | Sep 24, 2026 | Other filings | SEC |
|---|
| 424B3 · Prospectus | Sep 23, 2026 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 22, 2026 | Current report | SEC |
|---|
| Change of Director's Interest Notices x 4 | Sep 22, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - RAD | Sep 16, 2026 | Other filings | ASX |
|---|
| RADOC New Class Options Range of Units and Top 20 Holders | Sep 16, 2026 | Securities holder registration report | ASX |
|---|
| Application for quotation of securities - RAD | Sep 16, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - RAD | Sep 16, 2026 | Financing | ASX |
|---|
| Share purchase plan completed | Sep 16, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 14, 2026 | Current report | SEC |
|---|
| F-3 · Registration statement | Sep 14, 2026 | Offer document | SEC |
|---|
| RAD oral presentation at SNO26 on RAD101 Phase IIb data | Sep 13, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 11, 2026 | Current report | SEC |
|---|
| Results of Meeting | Sep 10, 2026 | Meeting outcome | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
|---|
| RAD Announces Positive Data from RAD301 P1 Imaging Trial | Sep 8, 2026 | Other filings | ASX |
|---|
| SCHEDULE 13G · Big-stake notice | Sep 4, 2026 | Big-stake notice | SEC |
|---|
| SCHEDULE 13D · Big-stake notice | Sep 4, 2026 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 28, 2026 | Current report | SEC |
|---|
| Appendix 4E and Preliminary Final Report | Aug 28, 2026 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 27, 2026 | Current report | SEC |
|---|
| Change of Director's Interest Notices x 4 | Aug 27, 2026 | Ownership change notice | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 26, 2026 | Current report | SEC |
|---|
| RAD Doses First Patient in Second Cohort of BetaBart (RV-01) | Aug 25, 2026 | Other filings | ASX |
|---|
| Ceasing to be a substantial holder | Aug 24, 2026 | Ownership change notice | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 20, 2026 | Current report | SEC |
|---|
| RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial | Aug 19, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 17, 2026 | Current report | SEC |
|---|
| Change in substantial holding | Aug 17, 2026 | Ownership change notice | ASX |
|---|
| RAD to meet with US FDA to align on RAD 101 Phase 3 Trial | Aug 16, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
|---|
| Notice of Extraordinary General Meeting and Proxy Form | Aug 12, 2026 | Proxy form | ASX |
|---|
| Share Purchase Plan - Now Open | Aug 6, 2026 | Financing | ASX |
|---|
| Update - Proposed issue of securities - RAD | Aug 4, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 3, 2026 | Current report | SEC |
|---|
| Application for quotation of securities - RAD | Aug 2, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 31, 2026 | Current report | SEC |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 30, 2026 | Quarterly report | ASX |
|---|
| Change in substantial holding | Jul 30, 2026 | Ownership change notice | ASX |
|---|
| Target market determination (TMD) | Jul 30, 2026 | Other filings | ASX |
|---|
| Prospectus | Jul 30, 2026 | Offer document | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 28, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 28, 2026 | Current report | SEC |
|---|
| Notice Under Section 708A | Jul 28, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - RAD | Jul 27, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 27, 2026 | Current report | SEC |
|---|
| 424B5 · Prospectus | Jul 27, 2026 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 24, 2026 | Current report | SEC |
|---|
| RAD completes A$12.5 M placement and launches A$6 M SPP | Jul 24, 2026 | Financing | ASX |
|---|
| 424B5 · Prospectus | Jul 23, 2026 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 22, 2026 | Current report | SEC |
|---|
| RAD Achieves Partial Response in Phase 1 Trial of RAD204 | Jul 21, 2026 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 6, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 30, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 3, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | May 6, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | May 6, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | May 1, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | Apr 30, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 23, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 20, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 16, 2026 | Current report | SEC |
|---|
| RAD Completes Enrollment in Phase 2b Trial of RAD 101 | Apr 15, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 8, 2026 | Current report | SEC |
|---|
| RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 | Apr 7, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 7, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 31, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 31, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 27, 2026 | Current report | SEC |
|---|
| RAD Doses First Patient in RAD 402 Phase 1 Clinical Study | Mar 26, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 24, 2026 | Current report | SEC |
|---|
| RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint | Mar 23, 2026 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 19, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 27, 2026 | Current report | SEC |
|---|
| Half Year Report and Appendix 4D 31 December 2025 | Feb 27, 2026 | Interim report | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 24, 2026 | Current report | SEC |
|---|
| RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study | Feb 23, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 28, 2026 | Current report | SEC |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 27, 2026 | Quarterly report | ASX |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 12, 2026 | Current report | SEC |
|---|
| SCHEDULE 13G · Big-stake notice | Jan 8, 2026 | Big-stake notice | SEC |
|---|
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
|---|
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
|---|
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
|---|
| 424B5 · Prospectus | Dec 23, 2025 | Offer document | SEC |
|---|
| CORRESP · Letter to the SEC | Dec 19, 2025 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Dec 19, 2025 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 19, 2025 | Current report | SEC |
|---|
| F-3 · Registration statement | Dec 17, 2025 | Offer document | SEC |
|---|
| F-3 · Registration statement | Dec 16, 2025 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 15, 2025 | Current report | SEC |
|---|
| RAD101 interim Phase 2b data - 92% achieve primary endpoint | Dec 14, 2025 | Other filings | ASX |
|---|
| 20-F/A · Annual report, amended | Dec 10, 2025 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 3, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 25, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 20, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 19, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 18, 2025 | Current report | SEC |
|---|
| RAD Approval for Phase 1 Therapeutic Trial of RAD 402 | Nov 17, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 17, 2025 | Current report | SEC |
|---|
| RAD Announces 50% Enrollment in Phase 2b Trial of RAD101 | Nov 16, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 12, 2025 | Current report | SEC |
|---|
| RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204 | Nov 11, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 4, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 3, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 28, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 22, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 20, 2025 | Current report | SEC |
|---|
| Prospectus | Oct 20, 2025 | Offer document | ASX |
|---|
| RAD completes A$35 M Placement and launches A$5 M SPP | Oct 19, 2025 | Financing | ASX |
|---|
| Trading Halt | Oct 15, 2025 | Trading halt or suspension | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 7, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 1, 2025 | Current report | SEC |
|---|
| Radiopharm received approval for RAD 202 trial acceleration | Sep 30, 2025 | Other filings | ASX |
|---|
| SPL:Research & Option Agreement with Radiopharm Theranostics | Sep 30, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 29, 2025 | Current report | SEC |
|---|
| 20-F · Annual report | Sep 17, 2025 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 17, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 15, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 29, 2025 | Current report | SEC |
|---|
| Appendix 4E and Preliminary Final Report | Aug 29, 2025 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 21, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 1, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 29, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 28, 2025 | Current report | SEC |
|---|
| RAD receives IND approval from US FDA for Betabart (RV-01) | Jul 27, 2025 | Other filings | ASX |
|---|
| SCHEDULE 13G · Big-stake notice | Jul 23, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 21, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 16, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 23, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 12, 2025 | Current report | SEC |
|---|
| RAD Granted US FDA Fast Track for RAD101 Metastases Imaging | Jun 10, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jun 10, 2025 | Current report | SEC |
|---|
| RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202 | Jun 3, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jun 3, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 2, 2025 | Current report | SEC |
|---|
| RAD Reports Positive Preclinical Lu177-B7H3-mAb Data | Jun 1, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | May 30, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 19, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 12, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
|---|
| Acceleration of RAD204 Phase 1 dose escalation trial | May 11, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 29, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 28, 2025 | Current report | SEC |
|---|
| First patient dosed in Phase IIb imaging for Brain Mets | Apr 27, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 17, 2025 | Current report | SEC |
|---|
| New RAD202 data confirms positive tumor uptake | Mar 16, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 13, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 7, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 28, 2025 | Current report | SEC |
|---|
| Half Year Report and Appendix 4D 31 December 2024 | Feb 28, 2025 | Interim report | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 25, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 24, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 18, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G · Big-stake notice | Feb 11, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 10, 2025 | Current report | SEC |
|---|
| Clinical trial data shows RAD 101 detects Brain Metastases | Feb 9, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 30, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G · Big-stake notice | Jan 29, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 21, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 10, 2025 | Current report | SEC |
|---|
| Lantheus increases shareholding in RAD with A$8m placement | Jan 9, 2025 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 30, 2024 | Current report | SEC |
|---|
| Strategic Co-Development Partnership with Lantheus for Aus | Dec 29, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 20, 2024 | Current report | SEC |
|---|
This page holds 200 of 290 filings.
All of its filings on SEC EDGAR